iShares 20+ Year Treasury Bond ETF (USD) The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in U.S. Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the U.S. Treasury that have a remaining maturity greater than or equal to twenty years.

iShares 20+ Year Treasury Bond ETF (USD) Active

null, San Francisco, DE, US

Stock Price USD

Price Change

Last Dividend USD

TLT's stock peer is HYG (iShares iBoxx $ High Yield Corporate Bond ETF)

TLT's stock peer is IEF (iShares 7-10 Year Treasury Bond ETF)

TLT's stock peer is IWM (iShares Russell 2000 ETF)

TLT's stock peer is LQD (iShares iBoxx $ Investment Grade Corporate Bond ETF)

TLT's stock peer is SHY (iShares 1-3 Year Treasury Bond ETF)

Financial Services Asset Management - Bonds

The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in U.S. Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the U.S. Treasury that have a remaining maturity greater than or equal to twenty years.

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
2025-06-02	2025-06-05	0.32	4.46 %	Monthly
2025-05-01	2025-05-06	0.33	4.27 %	Monthly
2025-04-01	2025-04-04	0.33	4.11 %	Monthly
2025-03-03	2025-03-06	0.29	4.05 %	Monthly
2025-02-03	2025-02-06	0.31	4.26 %	Monthly
2024-12-18	2024-12-23	0.35	4.21 %	Monthly
2024-12-02	2024-12-05	0.33	3.96 %	Monthly
2024-11-01	2024-11-06	0.31	4.05 %	Monthly
2024-10-01	2024-10-04	0.32	3.71 %	Monthly
2024-09-03	2024-09-06	0.31	3.70 %	Monthly
2024-08-01	2024-08-06	0.31	3.77 %	Monthly
2024-07-01	2024-07-05	0.29	3.95 %	Monthly
2024-06-03	2024-06-07	0.31	3.56 %	Monthly
2024-05-02	2024-05-07	0.31	3.96 %	Monthly
2024-04-02	2024-04-05	0.31	3.75 %	Monthly
2024-03-04	2024-03-07	0.30	3.62 %	Monthly
2024-02-02	2024-02-07	0.31	3.44 %	Monthly
2023-12-15	2023-12-20	0.31	3.64 %	Monthly
2023-12-04	2023-12-07	0.29	3.54 %	Monthly
2023-11-02	2023-11-07	0.29	4.09 %	Monthly
2023-10-03	2023-10-06	0.28	3.68 %	Monthly
2023-09-05	2023-09-08	0.29	3.33 %	Monthly
2023-08-02	2023-08-07	0.28	3.17 %	Monthly
2023-07-05	2023-07-10	0.28	2.98 %	Monthly
2023-06-02	2023-06-07	0.27	3.11 %	Monthly
2023-05-02	2023-05-05	0.27	2.84 %	Monthly
2023-04-04	2023-04-07	0.27	2.69 %	Monthly
2023-03-02	2023-03-07	0.25	2.79 %	Monthly
2023-02-02	2023-02-07	0.28	2.53 %	Monthly
2022-12-16	2022-12-21	0.26	2.61 %	Monthly
2022-12-02	2022-12-07	0.24	2.42 %	Monthly
2022-11-02	2022-11-07	0.24	2.59 %	Monthly
2022-10-04	2022-10-07	0.24	2.36 %	Monthly
2022-09-02	2022-09-08	0.24	2.36 %	Monthly
2022-08-02	2022-08-05	0.21	1.96 %	Monthly
2022-07-05	2022-07-08	0.23	2.00 %	Monthly
2022-06-02	2022-06-07	0.21	2.13 %	Monthly
2022-05-03	2022-05-06	0.20	1.94 %	Monthly
2022-04-04	2022-04-07	0.20	1.71 %	Monthly
2022-03-02	2022-03-07	0.18	1.59 %	Monthly
2022-02-02	2022-02-07	0.20	1.58 %	Monthly
2021-12-17	2021-12-22	0.17	1.60 %	Monthly
2021-12-02	2021-12-07	0.18	1.56 %	Monthly
2021-11-02	2021-11-05	0.19	1.50 %	Monthly
2021-10-04	2021-10-07	0.18	1.49 %	Monthly
2021-09-02	2021-09-08	0.19	1.57 %	Monthly
2021-08-03	2021-08-06	0.18	1.43 %	Monthly
2021-07-02	2021-07-08	0.19	1.50 %	Monthly
2021-06-02	2021-06-07	0.20	1.57 %	Monthly
2021-05-04	2021-05-07	0.20	1.57 %	Monthly
2021-04-05	2021-04-08	0.19	1.77 %	Monthly
2021-03-02	2021-03-05	0.17	1.75 %	Monthly
2021-02-02	2021-02-05	0.18	1.51 %	Monthly
2020-12-18	2020-12-23	0.16	1.65 %	Monthly
2020-12-02	2020-12-07	0.16	1.54 %	Monthly
2020-11-03	2020-11-06	0.17	1.57 %	Monthly
2020-10-02	2020-10-07	0.17	1.58 %	Monthly
2020-09-02	2020-09-08	0.18	1.62 %	Monthly
2020-08-04	2020-08-07	0.19	1.61 %	Monthly
2020-07-02	2020-07-08	0.19	1.72 %	Monthly
2020-06-02	2020-06-05	0.21	1.77 %	Monthly
2020-05-04	2020-05-07	0.22	1.75 %	Monthly
2020-04-02	2020-04-07	0.24	1.78 %	Monthly
2020-03-03	2020-03-06	0.23	1.96 %	Monthly
2020-02-04	2020-02-07	0.24	2.09 %	Monthly
2019-12-20	2019-12-26	0.22	2.25 %	Monthly
2019-12-03	2019-12-06	0.24	2.27 %	Monthly
2019-11-04	2019-11-07	0.25	2.25 %	Monthly
2019-10-02	2019-10-07	0.25	2.41 %	Monthly
2019-09-04	2019-09-09	0.26	2.18 %	Monthly
2019-08-02	2019-08-07	0.26	2.57 %	Monthly
2019-07-02	2019-07-08	0.26	2.43 %	Monthly
2019-06-04	2019-06-07	0.27	2.44 %	Monthly
2019-05-02	2019-05-07	0.26	2.83 %	Monthly
2019-04-02	2019-04-05	0.28	2.61 %	Monthly
2019-03-04	2019-03-07	0.25	2.72 %	Monthly
2019-02-04	2019-02-07	0.27	2.66 %	Monthly
2018-12-19	2018-12-24	0.28	2.89 %	Monthly
2018-12-04	2018-12-07	0.27	2.74 %	Monthly
2018-11-02	2018-11-07	0.27	3.02 %	Monthly
2018-10-02	2018-10-05	0.26	2.71 %	Monthly
2018-09-05	2018-09-10	0.27	2.62 %	Monthly
2018-08-02	2018-08-07	0.27	2.87 %	Monthly
2018-07-03	2018-07-09	0.27	2.58 %	Monthly
2018-06-04	2018-06-07	0.28	2.59 %	Monthly
2018-05-02	2018-05-07	0.26	2.83 %	Monthly
2018-04-03	2018-04-06	0.26	2.54 %	Monthly
2018-03-02	2018-03-07	0.24	2.59 %	Monthly
2018-02-02	2018-02-07	0.25	2.55 %	Monthly
2017-12-22	2017-12-28	0.26	2.72 %	Monthly
2017-12-04	2017-12-07	0.25	2.48 %	Monthly
2017-11-02	2017-11-07	0.26	2.70 %	Monthly
2017-10-03	2017-10-06	0.25	2.50 %	Monthly
2017-09-06	2017-09-08	0.26	2.45 %	Monthly
2017-08-03	2017-08-07	0.27	2.48 %	Monthly
2017-07-06	2017-07-10	0.26	2.48 %	Monthly
2017-06-05	2017-06-07	0.26	2.70 %	Monthly
2017-05-03	2017-05-05	0.25	2.55 %	Monthly
2017-04-05	2017-04-07	0.25	2.54 %	Monthly
2017-03-03	2017-03-07	0.23	2.60 %	Monthly
2017-02-03	2017-02-07	0.26	2.62 %	Monthly
2016-12-27	2016-12-29	0.31	2.85 %	Monthly
2016-12-05	2016-12-07	0.24	2.57 %	Monthly
2016-11-03	2016-11-07	0.25	2.34 %	Monthly
2016-10-05	2016-10-07	0.25	2.25 %	Monthly
2016-09-06	2016-09-08	0.25	2.21 %	Monthly
2016-08-03	2016-08-05	0.26	2.22 %	Monthly
2016-07-06	2016-07-08	0.26	2.21 %	Monthly
2016-06-03	2016-06-07	0.27	2.38 %	Monthly
2016-05-04	2016-05-06	0.26	2.43 %	Monthly
2016-04-05	2016-04-07	0.27	2.38 %	Monthly
2016-03-03	2016-03-07	0.25	2.62 %	Monthly
2016-02-03	2016-02-05	0.24	2.46 %	Monthly
2015-12-29	2015-12-31	0.25	2.80 %	Monthly
2015-12-03	2015-12-07	0.26	2.79 %	Monthly
2015-11-04	2015-11-06	0.27	2.60 %	Monthly
2015-10-05	2015-10-07	0.26	2.82 %	Monthly
2015-09-03	2015-09-08	0.26	2.65 %	Monthly
2015-08-05	2015-08-07	0.27	2.62 %	Monthly
2015-07-06	2015-07-08	0.26	3.08 %	Monthly
2015-06-03	2015-06-05	0.26	2.73 %	Monthly
2015-05-05	2015-05-07	0.26	2.69 %	Monthly
2015-04-06	2015-04-08	0.27	2.75 %	Monthly
2015-03-04	2015-03-06	0.25	2.85 %	Monthly
2015-02-04	2015-02-06	0.28	2.45 %	Monthly
2014-12-29	2014-12-31	0.26	2.98 %	Monthly
2014-12-03	2014-12-05	0.28	2.83 %	Monthly
2014-11-05	2014-11-07	0.29	2.92 %	Monthly
2014-10-03	2014-10-07	0.29	3.17 %	Monthly
2014-09-04	2014-09-08	0.27	2.96 %	Monthly
2014-08-05	2014-08-07	0.30	3.02 %	Monthly
2014-07-03	2014-07-08	0.29	3.28 %	Monthly
2014-06-04	2014-06-06	0.29	3.00 %	Monthly
2014-05-05	2014-05-07	0.27	3.01 %	Monthly
2014-04-03	2014-04-07	0.28	3.12 %	Monthly
2014-03-05	2014-03-07	0.26	3.06 %	Monthly
2014-02-05	2014-02-07	0.28	3.05 %	Monthly
2013-12-30	2014-01-02	0.34	3.51 %	Monthly
2013-12-04	2013-12-06	0.31	3.14 %	Monthly
2013-11-05	2013-11-07	0.29	2.77 %	Monthly
2013-10-03	2013-10-07	0.28	2.98 %	Monthly
2013-09-05	2013-09-09	0.28	2.76 %	Monthly
2013-08-05	2013-08-07	0.27	2.98 %	Monthly
2013-07-03	2013-07-08	0.25	2.60 %	Monthly
2013-06-05	2013-06-07	0.28	2.52 %	Monthly
2013-05-03	2013-05-07	0.26	2.55 %	Monthly
2013-04-03	2013-04-05	0.26	2.45 %	Monthly
2013-03-05	2013-03-07	0.25	2.47 %	Monthly
2013-02-05	2013-02-07	0.26	2.55 %	Monthly
2012-12-28	2013-01-02	0.27	2.75 %	Monthly
		0.24	2.48 %	Quarterly
2012-10-03	2012-10-05	0.26	2.76 %	Monthly
2012-09-06	2012-09-10	0.27	2.73 %	Monthly
2012-08-03	2012-08-07	0.27	2.74 %	Monthly
2012-07-05	2012-07-09	0.27	2.84 %	Monthly
2012-06-05	2012-06-07	0.26	2.79 %	Monthly
		0.28	3.20 %	Monthly
		0.29	3.41 %	Monthly
2012-03-05	2012-03-07	0.27	3.39 %	Monthly
		0.29	3.33 %	Monthly
2011-12-29	2012-01-04	0.38	3.64 %	Monthly
2011-12-05	2011-12-07	0.29	3.36 %	Monthly
2011-11-03	2011-11-07	0.30	3.34 %	Monthly
2011-10-05	2011-10-07	0.31	3.24 %	Monthly
		0.32	4.05 %	Monthly
2011-08-03	2011-08-05	0.33	4.15 %	Monthly
2011-07-06	2011-07-08	0.32	4.37 %	Monthly
2011-06-03	2011-06-07	0.35	4.51 %	Monthly
		0.40	4.33 %	Monthly
2011-04-05	2011-04-07	0.39	4.31 %	Monthly
		0.30	4.25 %	Monthly
		0.32	4.33 %	Monthly
		0.32	4.63 %	Monthly
		0.34	4.41 %	Monthly
		0.31	3.90 %	Monthly
		0.39	3.70 %	Monthly
2010-09-03	2010-09-08	0.32	3.86 %	Monthly
		0.32	3.82 %	Monthly
		0.32	3.71 %	Monthly
		0.33	3.88 %	Monthly
		0.32	4.08 %	Monthly
		0.33	4.52 %	Monthly
		0.29	4.35 %	Monthly
		0.33	4.04 %	Monthly
		0.32	4.51 %	Monthly
		0.31	4.28 %	Monthly
2009-11-04	2009-11-06	0.31	3.97 %	Monthly
		0.31	4.14 %	Monthly
		0.31	3.98 %	Monthly
2009-08-05	2009-08-07	0.32	4.14 %	Monthly
		0.30	4.46 %	Monthly
		0.31	4.28 %	Monthly
		0.30	4.03 %	Monthly
		0.30	4.10 %	Monthly
		0.28	3.93 %	Monthly
		0.28	3.91 %	Monthly
		0.41	3.45 %	Monthly
		0.35	3.77 %	Monthly
		0.37	4.47 %	Monthly
		0.29	4.36 %	Monthly
		0.34	4.48 %	Monthly
2008-08-05	2008-08-07	0.33	4.64 %	Monthly
		0.33	4.64 %	Monthly
		0.33	4.71 %	Monthly
		0.34	4.59 %	Monthly
		0.41	4.53 %	Monthly
		0.35	4.45 %	Monthly
		0.33	4.37 %	Monthly
		0.36	4.94 %	Monthly
		0.38	4.36 %	Monthly
		0.39	4.90 %	Monthly
		0.34	4.56 %	Monthly
		0.36	4.58 %	Monthly
		0.34	5.04 %	Monthly
2007-07-05	2007-07-09	0.33	4.75 %	Monthly
		0.34	4.73 %	Monthly
		0.32	4.94 %	Monthly
2007-04-04	2007-04-09	0.33	4.60 %	Monthly
		0.34	4.51 %	Monthly
		0.35	4.63 %	Monthly
2006-12-29	2007-01-05	0.30	4.93 %	Monthly
2006-12-05	2006-12-07	0.34	4.46 %	Monthly
2006-11-03	2006-11-07	0.35	5.02 %	Monthly
2006-10-04	2006-10-06	0.35	4.67 %	Monthly
		0.35	4.77 %	Monthly
2006-08-03	2006-08-07	0.34	4.87 %	Monthly
2006-07-06	2006-07-10	0.33	4.97 %	Monthly
		0.33	5.40 %	Monthly
2006-05-03	2006-05-05	0.33	5.04 %	Monthly
2006-04-05	2006-04-07	0.33	4.84 %	Monthly
2006-03-03	2006-03-07	0.32	4.63 %	Monthly
		0.32	4.61 %	Monthly
		0.38	4.91 %	Monthly
2005-12-05	2005-12-07	0.39	4.62 %	Monthly
2005-11-03	2005-11-07	0.40	4.59 %	Monthly
		0.36	4.46 %	Monthly
		0.33	4.64 %	Monthly
		0.34	4.41 %	Monthly
		0.33	4.27 %	Monthly
		0.35	4.58 %	Monthly
		0.33	4.39 %	Monthly
		0.33	4.52 %	Monthly
		0.28	4.92 %	Monthly
		0.34	4.53 %	Monthly
2005-01-04	2005-01-06	0.34	4.68 %	Monthly
		0.35	4.87 %	Monthly
2004-11-03	2004-11-05	0.37	4.82 %	Monthly
2004-10-05	2004-10-07	0.36	4.86 %	Monthly
2004-09-03	2004-09-08	0.35	4.87 %	Monthly
2004-08-04	2004-08-06	0.33	5.07 %	Monthly
		0.34	5.19 %	Monthly
		0.32	5.30 %	Monthly
		0.33	5.30 %	Monthly
2004-04-05	2004-04-07	0.35	5.14 %	Monthly
2004-03-01		0.36	5.60 %	Monthly
2004-02-02		0.36	5.30 %	Monthly
2003-12-31		0.40	5.83 %	Monthly
		0.42	5.44 %	Monthly
2003-11-03		0.35	5.39 %	Monthly
2003-10-01		0.37	5.64 %	Monthly
2003-09-04		0.37	5.57 %	Monthly
2003-08-05	2003-08-12	0.38	5.08 %	Monthly
2003-07-01		0.35	4.16 %	Monthly
		0.40	3.70 %	Monthly
2003-05-01		0.47	3.44 %	Monthly
2003-04-01		0.38	2.94 %	Monthly
		0.34	2.45 %	Monthly
2003-02-03		0.31	2.13 %	Monthly
2003-01-03	2003-01-10	0.45	1.77 %	Monthly
2002-12-02		0.39	1.32 %	Monthly
2002-11-01		0.39	0.85 %	Monthly
2002-10-01		0.34	0.39 %	Monthly
2002-09-03		0.37	0.42 %	Monthly

Recent News

Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments

Ruvidar(TM) demonstrates higher efficacy in the treatment of Herpes Simplex Virus, Type 1 versus FDA-approved, standard of care treatments Acyclovir and Abreva in a preclinical animal model. Toronto, Ontario--(Newsfile Corp. - April 10, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that RuvidarTM has been proven more effective in the treatment of Herpes Simplex Virus, Type 1 ("HSV-1") versus FDA-approved, standard of care treatments Acyclovir (5%) and Abreva (10% Docosanol) in a preclinical animal model.

2025-04-10 07:00:00

Ruvidar Demonstrates 7 Year Complete Response

Patient Diagnosed with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ Treated Once with Light-Activated Ruvidar(TM) Demonstrates 7 Year Complete Response Toronto, Ontario--(Newsfile Corp. - April 7, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that a patient enrolled in the Phase Ib Non-Muscle Invasive Bladder Cancer ("NMIBC") clinical study (A Phase 1b Clinical Study of Intravesical Photodynamic Therapy in Patients with Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer - ScienceDirect) has demonstrated a sustained Complete Response ("CR") (negative cystoscopy and negative urine cytology) lasting over 7 years. The patient was diagnosed with Bacillus Calmette-Guérin ("BCG")-Unresponsive NMIBC Carcinoma In-Situ ("CIS") and was treated once with the therapeutic dose of Theralase®'s lead small molecule RuvidarTM, which was subsequently activated with the TLC-3200 medical laser system.

2025-04-07 07:00:00

Ruvidar Effective in the Treatment of Herpes

Ruvidar(TM) demonstrates higher efficacy in the treatment of Herpes Simplex Virus, Type 1 versus the standard of care treatments Acyclovir and Abreva in a preclinical animal model. Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that RuvidarTM has demonstrated a higher efficacy in the treatment of Herpes Simplex Virus, Type 1 ("HSV-1") versus standard of care treatments Acyclovir (1%) and Abreva in a preclinical animal model.

2025-03-24 07:00:00

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions